Task: Answer Verification
Input (English): Question: Does oregovomab maintenance monoimmunotherapy improve outcomes in advanced ovarian cancer?
Answer: Although oregovomab has demonstrated bioactivity, the strategy of monoimmunotherapy is not effective as maintenance therapy after front-line treatment of a favorable subset of patients with advanced ovarian cancer. Future studies of this or other tumor-antigen specific immunization strategies should seek ways to further augment induced immunity.
Output (English): no